Jeff Evanson, CHIEF COMMERCIAL OFFICER at Outlook Therapeutics, Inc. (OTLK), bought 62,484 shares at $0.42 ($26K) on 2024-03-07, disclosed to the SEC on 2024-03-11.
Open-market purchase of $26k OTLK by CHIEF COMMERCIAL OFFICER. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| OTLK | BUY | 2021-12-06 | $47K | — | Filing → |
| OTLK | SELL | 2021-02-25 | $18K | — | Filing → |
| OTLK | SELL | 2021-02-17 | $291K | — | Filing → |